Fertility issues in cancer survivorship

CA Cancer Journal for Clinicians

Volumn 64, Issue 2, 2014, Pages 118-134

  Kort, Jonathan D ^a   Eisenberg, Michael L ^b   Millheiser, Leah S ^a   Westphal, Lynn M ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complications and late effects of therapy; Fertility preservation; Pregnancy; Reproductive health

Indexed keywords

ALKYLATING AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT;

AMENORRHEA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CRYOPRESERVATION; DRUG CYTOTOXICITY; FEMALE GENITAL SYSTEM; FERTILITY PRESERVATION; FERTILIZATION IN VITRO; GENETIC ANALYSIS; GONAD DYSFUNCTION; GONAD FUNCTION; HEALTH STATUS; HUMAN; MENARCHE; NONHUMAN; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY FUNCTION; OVARY HYPERSTIMULATION; PARENT COUNSELING; PREIMPLANTATION EMBRYO; PREPREGNANCY CARE; PREPUBERTY; PRIORITY JOURNAL; PROGENY; QUALITY OF LIFE; RADIATION INJURY; REPRODUCTIVE HEALTH; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SEXUAL HEALTH; SPERM PRESERVATION; SPERMATOGENESIS;

COMPLICATIONS AND LATE EFFECTS OF THERAPY; FERTILITY PRESERVATION; PREGNANCY; REPRODUCTIVE HEALTH;

FEMALE; HUMANS; INFERTILITY, FEMALE; INFERTILITY, MALE; MALE; NEOPLASMS; SURVIVORS;

EID: 84899456397     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21205     Document Type: Review

References (183)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006; 24: 2917-2931.
3. National Cancer Institute. Surveillance, Epidemiology, and End Results. SEER 9. Fast Stats. seer.cancer.gov/faststats/selections.php ?. Accessed June 20, 2013.
4. De Vos M, Devroey P, Fauser BC,. Primary ovarian insufficiency. Lancet. 2010; 376: 911-921.
5. Schover LR, Rybicki LA, Martin BA, Bringelsen KA,. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer. 1999; 86: 697-709.
6. Canada AL, Schover LR,. The psychosocial impact of interrupted childbearing in long-term female cancer survivors. Psychooncology. 2012; 21: 134-143.
7. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004; 22: 4174-4183.
8. The Quality Oncology Practice Initiative. Summary of the Measures. qopi.asco.org/Documents/QOPISpring2011MeasuresSummary-000.pdf. Accessed June 20, 2013.
9. Quinn GP, Vadaparampil ST, Gwede CK, et al. Discussion of fertility preservation with newly diagnosed patients: oncologists' views. J Cancer Surviv. 2007; 1: 146-155.
10. Duffy CM, Allen SM, Clark MA,. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol. 2005; 23: 766-773.
11. American Society for Reproductive Medicine. Fertility Experts Issue New Report on Egg Freezing: ASRM Lifts Experimental Label From Technique. asrm.org/Fertility-Experts-Issue-New-Report-on-Egg-Freezing-ASRM-Lifts- Experimental-Label-from-Technique/. Accessed June 20, 2013.
12. Quinn GP, Vadaparampil ST, King L, et al. Impact of physicians' personal discomfort and patient prognosis on discussion of fertility preservation with young cancer patients. Patient Educ Couns. 2009; 77: 338-343.
13. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF,. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause, Hum Reprod. 1992;7: 1342-1346.
14. The ovary. In:, Speroff L, Glass RH, Kase NG, eds. Clinical Gynecologic Endocrinology and Infertility. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 1999: 114-120.
15. te Velde ER, Scheffer GJ, Dorland M, Broekmans FJ, Fauser BC,. Developmental and endocrine aspects of normal ovarian aging. Mol Cell Endocrinol. 1998; 145: 67-73.
16. La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010; 16: 113-130.
17. Gougeon A,. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev. 1996; 17: 121-155.
18. Broekmans FJ, Faddy MJ, Scheffer G, te Velde ER,. Antral follicle counts are related to age at natural fertility loss and age at menopause. Menopause. 2004; 11: 607-614.
19. Seifer DB, MacLaughlan DT,. Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. 2007; 88: 539-547.
20. Seifer DB, Baker VL, Leader B,. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril. 2011; 95: 747-750.
21. Levine J,. Gonadotoxicity of cancer therapies in pediatric and reproductive-aged females. In:, Gracia C, Woodruff TK, eds. Oncofertility and Medical Practice: Clinical Issues and Implementation. New York: Springer; 2012: 3-12.
22. Rivkees SA, Crawford JD,. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988; 259: 2123-2125.
23. Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006; 91: 1723-1728.
24. Sklar CA,. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr. 2005; 34: 25-27.
25. Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006; 98: 890-896.
26. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N,. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999; 17: 2365-2370.
27. Letourneau JM, Ebbel EE, Katz PP, et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012; 118: 1933-1939.
28. Meirow D, Lewis H, Nugent D, Epstein M,. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod. 1999; 14: 1903-1907.
29. Gosden RG, Wade JC, Fraser HM, Sandow J, Faddy MJ,. Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary. Hum Reprod. 1997; 12: 2483-2488.
30. Meirow D, Nugent D,. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001; 7: 535-543.
31. Green DM, Sklar CA, Boice JD, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009; 27: 2374-2381.
32. Wallace WH, Shalet SM, Hendry JH, Morris-Jones PH, Gattamaneni HR,. Ovarian failure following abdominal irradiation in childhood: the radiosensitivity of the human oocyte. Br J Radiol. 1989; 62: 995-998.
33. Wallace WH, Shalet SM, Hendry JH, Morris-Jones PH, Gattamaneni HR,. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005; 62: 738-744.
34. Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R,. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant. 1998; 21: 287-290.
35. Gareer W, Gad Z, Gareer H,. Needle oophoropexy: a new simple technique for ovarian transposition prior to pelvic irradiation. Surg Endosc. 2011; 25: 2241-2246.
36. Hadar H, Loven D, Herskovitz P, Bairey O, Yagoda A, Levavi H,. An evaluation of lateral and medial transposition of the ovaries out of radiation fields. Cancer. 1994; 74: 774-779.
37. Bisharah M, Tulandi T,. Laparoscopic preservation of ovarian function: an underused procedure. Am J Obstet Gynecol. 2003; 188: 367-370.
38. Chemaitilly W, Sklar CA,. Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer. 2010; 17: 141-159.
39. Hawkins MM, Smith RA,. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer. 1989; 43: 399-402.
40. Bath LE, Critchley HO, Chambers SE, Anderson RA, Kelnar CJ, Wallace WB,. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol. 1999; 106: 1265-1272.
41. Louis J, Limarzi J, Best WR,. Treatment of chronic granulocytic leukaemia with Myleran. Arch Intern Med. 1956; 97: 299-308.
42. Olive DL,. Reproductive physiology. In:, Berek JS, ed. Berek and Novak's Gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2007: 161-186.
43. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM,. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod. 1993; 8: 2080-2087.
44. Epstein RJ,. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol. 1990; 8: 2062-2084.
45. Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007; 22: 1626-1633.
46. Meirow D, Biederman H, Anderson R, Wallace H,. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010; 53: 727-739.
47. Fertile Hope. Risk Calculator. fertilehope.org/tool-bar/risk-calculator. cfm. Accessed June 20, 2013.
48. Newman H, Finger PT, Chin KJ, Pavlick AC,. Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma. Eur J Ophthalmol. 2011; 21: 796-801.
49. Genentech, Inc. Avastin (Bevacizumab) Prescribing Information. gene.com/download/pdf/avastin-prescribing.pdf. Accessed June 20, 2013.
50. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH,. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010; 116: 791-798.
51. Zamah AM, Mauro MJ, Druker BJ, et al. Will imatinib compromise reproductive capacity? Oncologist. 2011; 16: 1422-1427.
52. Gonfloni S, Di Tella L, Caldarola S, et al. Inhibition of the c-Abl-Tap63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009; 15: 1179-1185.
53. Hensley ML, Ford JM,. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003; 40 (2 suppl 2): 21-25.
54. Davies C, Pan H, Godwin J,; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381: 805-816.
55. Schover LR,. Motivation for parenthood after cancer: a review. J Natl Cancer Inst Monogr. 2005;(3 4): 2-5.
56. Gorman JR, Maclarne VL, Roesch SC, Madlensky L, Pierce JP,. Depressive symptoms among young breast cancer survivors: the importance of reproductive concerns. Breast Cancer Res Treat. 2010; 123: 477-485.
57. Loren AW, Mangu PB, Beck LN, et al. American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2500-2510.
58. Dolmans MM, Demylle D, Martinez-Madrid B, Donnez J,. Efficacy of in vitro fertilization after chemotherapy. Fertil Steril. 2005; 83: 897-901.
59. Ginsburg ES, Yanushpolsky EH, Jackson KV,. In vitro fertilization for cancer patients and survivors. Fertil Steril. 2001; 75: 705-710.
60. Baynosa J, Westphal LM, Madrigrano A, Wapnir I,. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg. 2009; 209: 603-607.
61. Madrigrano A, Westphal LM, Wapnir I,. Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg. 2007; 194: 477-481.
62. First baby born of frozen embryo. New York Times. April 11, 1984. Accessed from: nytimes.com/1984/04/11/us/first-baby-born-of-frozen-embryo.html Accessed June 20, 2013.
63. Society for Assisted Reproductive Technology. SART 2010 National Data Summary. sartcorsonline.com/rptCSR-PublicMultYear.aspx?ClinicPKID=0. Accessed June 20, 2013.
64. Roque M, Lattes K, Serra S, et al. Fresh embryo transfer versus frozen embryo transfer in in-vitro fertilization: a systematic review and meta-analysis. Fertil Steril. 2013; 99: 156-162.
65. Westphal LM, Massie JAM,. Embryo and oocyte banking. In:, Gracia C, Woodruff TK, eds. Oncofertility Medical Practice: Clinical Issues and Implementation. New York: Springer; 2012: 51-62.
66. Sonmezer M, Oktay K,. Fertility preservation in female patients. Hum Reprod Update. 2004; 10: 251-266.
67. Brinsden PR, Wada I, Tan SL, Balen A, Jacobs HS,. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol. 1995; 102: 767-772.
68. Friedman B, Pao S, Wesphal LM, Lathi RB,. Oocyte retrieval following continued stimulation five days beyond ovulation yields live birth after frozen embryo transfer. J Assist Reprod Genet. 2012; 29: 433-435.
69. Pal L, Leykin L, Schifren JL, et al. Malignancy may adversely influence the quality and behavior of oocytes. Hum Reprod. 1998; 13: 1837-1840.
70. Quintero RB, Helmer A, Huang JQ, Westphal LM,. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010; 93: 865-868.
71. Almog B, Azem F, Gordon D, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril. 2012; 98: 957-960.
72. Pena JE, Chang PL, Chan LK, Zeitoun K, Thornton MH, Sauer MV,. Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles. Hum Reprod. 2002; 17: 83-87.
73. Azim AA, Constantini-Ferrando M, Lostritto K, Oktay K,. Relative potencies of anastrazole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocr Metab. 2007; 92: 2197-2200.
74. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z,. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003; 18: 90-95.
75. Induction of ovulation. In:, Speroff L, Glass RH, Kase NG, eds. Clinical Gynecologic Endocrinology and Infertility. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 1999: 1097-1125.
76. Michaan N, Ben-David G, Ben-Yosef D, et al. Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients. Eur J Obstet Gynecol Reprod Biol. 2010; 149: 175-177.
77. Chen C,. Pregnancy after human oocyte cryopreservation. Lancet. 1986; 19: 1884-1886.
78. Edgar DH, Good DA,. A critical appraisal of cryopreservation (slow cooling versus vitrification) of human oocytes and embryos. Hum Reprod Update. 2012; 18: 536-554.
79. Gook DA, Osborn SM, Johnston WI,. Cryopreservation of mouse and human oocytes using 1,2-propanediol and the configuration of the meiotic spindle. Hum Reprod. 1993; 8: 1101-1109.
80. Cobo A, Rubio C, Gerli S, Ruiz A, Pellicer A, Remohi J,. Use of fluorescence in situ hybridization to assess the chromosomal status of embryos obtained from cryopreserved oocytes. Fertil Steril. 2001; 75: 354-360.
81. Notrica J, Divita A, Neuspiller F, Arenas G, de Fried EP,. Healthy girl born after cryopreservation of gametes and ICSI in a patient with seminoma. Reprod Biomed Online. 2004; 9: 620-622.
82. Liebermann J, Nawroth F, Isachenko V, Isachenko E, Rahimi G, Tucker MJ,. Potential importance of vitrification in reproductive medicine. Biol Reprod. 2002; 67: 1671-1680.
83. Trokoudes KM, Pavlides C, Zhang X,. Comparison outcome of fresh and vitrified donor oocytes in an egg-sharing donation program. Fertil Steril. 2011; 95: 1996-2000.
84. Nagy ZP, Chang CC, Shapiro DB, et al. Clinical evaluation of the efficiency of an oocyte donation program using egg cryo-banking. Fertil Steril. 2008; 92: 520-526.
85. Cobo A, Kuwayama M, Perez S, Ruiz A, Pellicer A, Remohi J,. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril. 2008; 6: 1657-1664.
86. Chian RC, Huang JY, Tan SL, et al. Obstetrical and perinatal outcome in 200 infants conceived from vitrified oocytes. Reprod Biomed Online. 2008; 16: 608-610.
87. Ethics Committee of the American Society for Reproductive Medicine. Posthumous collection and use of reproductive tissue: a committee opinion. Fertil Steril. 2013; 99: 1842-1845.
88. American Childhood Cancer Organization. Childhood Cancer Statistics. acco.org/Information/AboutChildhoodCancer/ChildhoodCancerStatistics.aspx. Accessed June 20, 2013.
89. Reichman DE, Davis OK, Zaninovic N, Rosenwaks Z, Goldschlag DE,. Fertility preservation using controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome. Fertil Steril. 2012; 98: 1225-1228.
90. Stoop D, De Vos M, Tournaye H, Devroey P,. Fertility preservation utilizing controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome. Fertil Steril. 2012; 98: 1121-1122.
91. Donnez J, Martinez-Madrid B, Jadoul P, Von Langendonckt A, Demylle D, Dolmans MM,. Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update. 2006; 12: 519-535.
92. Oktay K, Karlikaya G,. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med. 2000; 342: 1919.
93. Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J,. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004; 364: 1405-1410.
94. Donnez J, Silber S, Andersen CY, et al. Children born after autotransplantation of cryopreserved ovarian tissue. A review of 13 live births. Ann Med. 2011; 43: 437-450.
95. Andersen CY, Silber SJ, Berghold SH, Jorgensen JS, Ernst E,. Long-term duration of function of ovarian tissue transplants: case reports. Reprod Biomed Online. 2012; 25: 128-132.
96. Feyereisen E, Steffann J, Romana S, et al. Five years' experience of preimplantation genetic diagnosis in the Parisian Center: outcome of the first 441 started cycles. Fertil Steril. 2007; 87: 60-73.
97. Nagy R, Sweet K, Eng C,. Highly penetrant hereditary cancer syndromes. Oncogene. 2004; 23: 6445-6470.
98. Ethics of preimplantation genetic diagnosis for cancer. Lancet Oncol. 2006; 7: 611.
99. Smith KR, Ellington L, Chan AY, Croyle RT, Botkin JR,. Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev. 2004; 13: 733-740.
100. SenGupta SB, Vadaparampil ST, Menon U,. Preimplantation genetic diagnosis for hereditary cancers. Adv Exp Med Biol. 2012; 732: 103-113.
101. Sonmezer M, Oktay K,. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006; 11: 422-434.
102. Bedawy A, Elnashar A, El-Ashry M, Shahat M,. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009; 91: 694-697.
103. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011; 95: 906-914.e1-4.
104. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012; 30: 533-538.
105. Meirow D, Rabinovici J, Katz D, Or R, Shufaro Y, Ben-Yehuda D,. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer. 2006; 107: 1634-1641.
106. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997; 15: 969-973.
107. Del Pup L,. Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients. Gynecol Endocrinol. 2012; 28: 740-745.
108. Agarwal A, Malvezzi H, Sharma R,. Effect of an isotonic lubricant on sperm collection and sperm quality. Fertil Steril. 2013; 99: 1581-1586.
109. Fobair P, Stewart SL, Chang S, D'Onofrio C, Banks PJ, Bloom JR,. Body image and sexual problems in young women with breast cancer. Psychooncology. 2006; 15: 579-594.
110. Ito TY, Polan ML, Whipple B, Trant AS,. The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status. J Sex Marital Ther. 2006; 32: 369-378.
111. Bolour SY, Braunstein GD,. Pharmacologic treatment options for hypoactive sexual desire disorder. Womens Health (Lond Engl). 2005; 1: 263-277.
112. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G,. Vaginal changes and sexuality in women with a history of cervical cancer. N Engl J Med. 1999; 340: 1383-1389.
113. Bober SL, Sanchez Varela V,. Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol. 2012; 30: 3712-3719.
114. Krychman M, Millheiser LS,. Sexual health issues in women with cancer. J Sex Med. 2013; 10 (suppl 1): 5-15.
115. Rosen A,. Third-party reproduction and adoption in cancer patients. J Natl Cancer Inst Monogr. 2005;(34): 91-93.
116. Wang E,. Pregnancy in cancer patients and survivors. In:, Gracia C, Woodruff TK, eds. Oncofertility and Medical Practice: Clinical Issues and Implementation. New York: Springer; 2012: 129-138.
117. Lie Fong S, van den Heuvel-Eibrink MM, Eijkemans MJ, Schipper I, Hukkelhoven CW, Laven JS,. Pregnancy outcome in female childhood cancer survivors. Hum Reprod. 2010; 25: 1206-1212.
118. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol. 2002; 187: 1070-1080.
119. Green DM, Peabody EM, Nan B, Peterson S, Kalapurakal JA, Breslow NE,. Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2002; 20: 2506-2513.
120. Reulen RC, Zeegers MP, Wallace WH, et al. British Childhood Cancer Survivor Study. Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2239-2247.
121. Clark H, Kurinczuk JJ, Lee AJ, Bhattacharya S,. Obstetrical outcomes in cancer survivors. Obstet Gynecol. 2007; 110: 849-854.
122. Madanat-Harjuoja LM, Lahteenmaki PM, Dyba T, Gissler M, Boice JD Jr, Malila N,. Stillbirth, early death and neonatal morbidity among offspring of female cancer survivors. Acta Oncol. 2013; 52: 1152-1159.
123. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309: 2371-2381.
124. Martin JA, Hambilton BE, Ventura SJ, Osterman MJK, Wilson EC, Matthews TJ,. Births: final data for 2010. Natl Vital Stat Rep. 2012; 61: 1-72.
125. Ventura SJ, Hamilton BE, Sutton PD,. Revised birth and fertility rates for the United States, 2000 and 2001. Natl Vital Stat Rep. 2003; 51: 1-18.
126. Salonia A, Capogrosso P, Castiglione F, et al. Sperm banking is of key importance in patients with prostate cancer. Fertil Steril. 2013; 100: 367-372.e1.
127. Weinbauer GF, Luetjens CM, Simoni M, Nieschlag E,. Physiology of testicular function. In:, Neischlag E, Behre HM, Nieschlag S, eds. Andrology: Male Reproductive Health and Dysfunction. New York: Springer; 2010: 11-59.
128. Williams DH, Karpman E, Sander JC, Spiess PE, Pisters LL, Lipshultz LI,. Pretreatment semen parameters in men with cancer. J Urol. 2009; 181: 736-740.
129. Dada R, Gupta NP, Kucheria K,. Spermatogenic arrest in men with testicular hyperthermia. Teratog Carcinog Mutagen. 2003; suppl 1: 235-243.
130. van der Kaaij MA, Heutte N, van Echten-Arends J, et al. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica. 2009; 94: 1691-1697.
131. Trost LW, Brannigan RE,. Oncofertility and the male cancer patient. Curr Treat Options Oncol. 2012; 13: 146-160.
132. Skakkebaek NE, Rajpert-De Meyts E, Main KM,. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod. 2001; 16: 972-978.
133. Matzuk MM, Lamb DJ,. The biology of infertility: research advances and clinical challenges. Nat Med. 2008; 14: 1197-1213.
134. Eisenberg ML, Betts P, Herder D, Lamb DJ, Lipshultz LI,. Increased risk of cancer among azoospermic men. Fertil Steril. 2013; 100: 681-685.e1.
135. Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP,. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol. 1997; 15: 239-245.
136. Marmor D, Duyck F,. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey. Andrologia. 1995; 27: 99-106.
137. Tal R, Botchan A, Hauser R, Yogev L, Paz G, Yavetz H,. Follow-up of sperm concentration and motility in patients with lymphoma. Hum Reprod. 2000; 15: 1985-1988.
138. Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant. 2002; 30: 447-451.
139. Howell SJ, Shalet SM,. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr. 2005;(34): 12-17.
140. Trottmann M, Becker AJ, Stadler T, et al. Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation. Eur Urol. 2007; 52: 355-367.
141. Daniell HW, Tam EW,. Testicular atrophy in therapeutic orchiectomy specimens from men with prostate carcinoma: association with prior prostate bed radiation and older age. Cancer. 1998; 83: 1174-1179.
142. Mydlo JH, Lebed B,. Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men? Scand J Urol Nephrol. 2004; 38: 221-224.
143. Hermann RM, Henkel K, Christiansen H, et al. Testicular dose and hormonal changes after radiotherapy of rectal cancer. Radiother Oncol. 2005; 75: 83-88.
144. Nishi Y, Hamamoto K, Fujita N, Okada S,. Empty sella/pituitary atrophy and endocrine impairments as a consequence of radiation and chemotherapy in long-term survivors of childhood leukemia. Int J Hematol. 2011; 94: 399-402.
145. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95: 2536-2559.
146. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL,. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004; 428: 145-150.
147. Brennemann W, Brensing KA, Leipner N, Boldt I, Klingmuller D,. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-Tryptophan-6 luteinizing hormone releasing hormone. Clin Investig. 1994; 72: 838-842.
148. Redman JR, Bajorunas DR,. Suppression of germ cell proliferation to prevent gonadal toxicity associated with cancer treatment. In: Workshop on Psychosexual and Reproductive issues Affecting Patients With Cancer. New York: American Cancer Society; 1987: 90-94.
149. Nicopoullos JD, Gilling-Smith C, Almeida PA, Norman-Taylor J, Grace I, Ramsay JW,. Use of surgical sperm retrieval in azoospermic men: a meta-analysis. Fertil Steril. 2004; 82: 691-701.
150. Schlegel PN,. Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision. Hum Reprod. 1999; 14: 131-135.
151. Pearce S, Steinberg Z, Eggener S,. Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection [published online ahead of print August 2, 2013]. Curr Urol Rep.
152. Hsiao W, Deveci S, Mulhall JP,. Outcomes of the management of post-chemotherapy retroperitoneal lymph node dissection-associated anejaculation. BJU Int. 2012; 110: 1196-1200.
153. Mazzola CR, Sheinfeld J, Carver B,. Ex-vivo testis sperm extraction in men undergoing orchiectomy for testis cancer. J Urol. 2012; 187: E802.
154. Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005; 93: 200-207.
155. Kiserud CE, Fossa A, Bjoro T, Holte H, Cvancarova M, Fossa SD,. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer. 2009; 100: 455-463.
156. Zaletel LZ, Bratanic N, Jereb B,. Gonadal function in patients treated for Hodgkin's disease in childhood. Radiol Oncol. 2010; 44: 187-193.
157. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR,. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006; 166: 1660-1665.
158. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007; 116: 2694-2701.
159. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol. 2005; 23: 3718-3725.
160. Gu Y, Liang X, Wu W, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab. 2009; 94: 1910-1915.
161. Hay CJ, Brady BM, Zitzmann M,. A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. J Clin Endocrinol Metab. 2005; 90: 2042-2049.
162. Brackett NL, Kafetsoulis A, Ibrahim E, Aballa TC, Lynne CM,. Application of 2 vibrators salvages ejaculatory failures to 1 vibrator during penile vibratory stimulation in men with spinal cord injuries. J Urol. 2007; 177: 660-663.
163. Schrader M, Muller M, Sofikitis N, Straub B, Krause H, Miller K,. "Onco-tese": testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines? Urology. 2003; 61: 421-425.
164. Devroey P, Liu J, Nagy Z, et al. Pregnancies after testicular sperm extraction and intracytoplasmic sperm injection in non-obstructive azoospermia. Hum Reprod. 1995; 10: 1457-1460.
165. Ramasamy R, Lin K, Gosden LV, Rosenwaks Z, Palermo GD, Schlegel PN,. High serum FSH levels in men with nonobstructive azoospermia does not affect success of microdissection testicular sperm extraction. Fertil Steril. 2009; 92: 590-593.
166. Ishikawa T,. Surgical recovery of sperm in non-obstructive azoospermia. Asian J Androl. 2012; 14: 109-115.
167. Damani MN, Master V, Meng MV, Burgess C, Turek P, Oates RD,. Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol. 2002; 20: 930-936.
168. Hsiao W, Stahl PJ, Osterberg EC, et al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience. J Clin Oncol. 2011; 29: 1607-1611.
169. Palermo G, Joris H, Devroey P, Van Steirteghem AC,. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992; 340: 17-18.
170. Chung K, Irani J, Knee G, Efymow B, Blasco L, Patrizio P,. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obstet Gynecol Reprod Biol. 2004; 113 (suppl 1): S7-S11.
171. van Casteren NJ, van Santbrink EJ, van Inzen W, Romijn JC, Dohle GR,. Use rate and assisted reproduction technologies outcome of cryopreserved semen from 629 cancer patients. Fertil Steril. 2008; 90: 2245-2250.
172. Meseguer M, Molina N, Garcia-Velasco JA, Remohi J, Pellicer A, Garrido N,. Sperm cryopreservation in oncological patients: a 14-year follow-up study. Fertil Steril. 2006; 85: 640-645.
173. Kelleher S, Wishart SM, Liu PY, et al. Long-term outcomes of elective human sperm cryostorage. Hum Reprod. 2001; 16: 2632-2639.
174. Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet. 1998; 62: 45-52.
175. Chow EJ, Kamineni A, Daling JR, et al. Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. Arch Pediatr Adolesc Med. 2009; 163: 887-894.
176. Stahl O, Boyd HA, Giwercman A, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst. 2011; 103: 398-406.
177. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer. Fertil Steril. 2005; 83: 1622-1628.
178. Hirsch M, Lunenfeld B, Modan M, Ovadia J, Shemesh J,. Spermarche-the age of onset of sperm emission. J Adolesc Health Care. 1985; 6: 35-39.
179. Ji CY, Ohsawa S,. Onset of the release of spermatozoa (spermarche) in Chinese male youth. Am J Hum Biol. 2000; 12: 577-587.
180. Hagenas I, Jorgensen N, Rechnitzer C, et al. Clinical and biochemical correlates of successful semen collection for cryopreservation from 12-18-year-old patients: a single-center study of 86 adolescents. Hum Reprod. 2010; 25: 2031-2038.
181. Hermann BP, Sukhwani M, Winkler F, et al. Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. Cell Stem Cell. 2012; 11: 715-726.
182. Jahnukainen K, Hou M, Petersen C, Setchell B, Soder O,. Intratesticular transplantation of testicular cells from leukemic rats causes transmission of leukemia. Cancer Res. 2001; 61: 706-710.
183. Sato T, Katagiri K, Gohbara A, et al. In vitro production of functional sperm in cultured neonatal mouse testes. Nature. 2011; 471: 504-507.